Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 10, 2000, Pages 1051-1054

  Zhao, Qiuyan ^a   Yu, Dong ^a   Agrawal, Sudhir ^a  

^a HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DINUCLEOSIDE PHOSPHORODITHIOATE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PROTEIN MODIFICATION; SPLEEN LYMPHOCYTE;

ANIMALS; BASE SEQUENCE; BIOLOGICAL RESPONSE MODIFIERS; CELLS, CULTURED; CPG ISLANDS; LYMPHOCYTES; MICE; OLIGODEOXYRIBONUCLEOTIDES; ORGANOTHIOPHOSPHORUS COMPOUNDS; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP; THIONUCLEOTIDES;

ANIMALIA;

EID: 0034657519     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00157-8     Document Type: Article

References (16)

1. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bisshop G.A., Teasdale R., Koretzky G.A., Klinman D.M. Nature. 374:1996;546.
2. Branda R.F., Moore A.L., Mathews L., McCormack J.J., Zon G. Biochem. Pharmacol. 45:1993;2037.
3. Pisetsky D.S., Reich C.F. Life Sci. 54:1994;101.
4. Zhao Q., Temsamani J., Iadarola P., Jiang Z., Agrawal S. Biochem. Pharmacol. 51:1996;173.
5. Zhao Q., Temsamani J., Zhou R.Z., Agrawal S. Antisense Nucleic Acid Drug Dev. 7:1997;495.
6. Hartmann G., Kreig A.M. J. Immunol. 164:2000;944.
7. Macfarlane D.E., Manzel L. J. Immunol. 160:1998;1122.
8. Manzel L., Macfarlane D.E. Antisense Nucleic Acid Drug Dev. 9:1999;459.
9. Dunford, P. J.; Mulqueen, M. J.; Agrawal, S. Targeting the Molecular Basis of Disease (Nature Biotechnology) Conference abstract, 1997; p 40.
10. Kreig A.M., Yi A.K., Hartmann G. Pharmacol. Ther. 84:1999;113.
11. Carpentier A.F., Chen L., Maltonti F., Delattre J.Y. Cancer Res. 59:1999;5429.
12. McCluskie M.J., Davis H.L. Vaccine. 18:1999;231.
13. Kline J.N., Krieg A.M., Waldschmidt T.J., Ballas Z.K., Jain V., Businga T.R. J. Allergy Clin. Immunol. 104:1999;1258.
14. Agrawal S., Zhao Q. Curr. Opin. Chem. Biol. 2:1998;519.
15. Zhao Q., Yu D., Agrawal S. Bioorg. Med. Chem. Lett. 9:1999;3453.
16. Oligonucleotides were synthesized on 1 μmol scale using an automated DNA synthesizer (Expedite 8909 PerSeptive Biosystems). Deoxynucleosides and 2′-O-methylribonucleoside phosphoramidites were obtained from PerSeptive Biosystems (Foster City, CA). 2′-O-methoxyethoxyribonucleoside and 3′-O-methylribonucleosides phosphoramidites were obtained from ChemGenes (Ashland, MA). Modified nucleosides were incorporated into the oligonucleotides at a specific site using normal coupling cycles. After the synthesis, oligonucleotides were deprotected using concentrated ammonium hydroxide and purified by reversed-phase HPLC, followed by dialysis. Purified oligonucleotides as sodium salt form were lyophilized prior to use. Purity of oligonucleotides was checked by CGE and MALDI-TOF MS (Bruker Proflex III MALDI-TOF Mass Spectrometer). Molecular weight observed and calculated (in brackets) for each oligonucleotide were as follows: oligo 1, 6041 (6043); oligo 2, 6075 (6073); oligo 3, 6075 (6073); oligo 4, 6060 (6059); oligo 5, 6061 (6059); oligo 6, 6060 (6059); oligo 7, 6075 (6073); oligo 8, 6075 (6073); oligo 9, 6061, (6059); oligo 10, 6075 (6073); oligo 11, 6060 (6059); oligo 12, 6193 (6191); oligo 13, 6178 (6177); oligo 14, 6327 (6327).